Everolimus Added to Exemestane Boosts Overall Response in Postmenopausal ... Medical News Today SAN ANTONIO, TX - The oral mammalian target of rapamycin inhibitor everolimus combined with the steroidal aromatase inhibitor exemestane significantly improves the overall response rate in postmenopausal women with advanced breast cancer, ... |
